[Pharmacokinetics of 14C-isosorbide dinitrate after administration in various sustained-release formulations]. 1983

L F Chasseaud, and T Taylor, and R M Major, and I W Taylor, and V Luckow, and A Darragh, and R F Lambe

To study the influence of various in vitro release rates and of coadministration with food on bioavailability of isosorbide dinitrate (ISDN; isoket retard 40) and its mononitrate metabolites from sustained-release formulations the pharmacokinetics of two experimental batches of tablets with different release rates containing 40 mg 14C-ISDN each were studied in six human volunteers. One of the formulations was not only administered after fasting but aslo with a standard meal. In all cases approx. 80% of the administered radioactivity were recovered in the urine and 5% in the faeces during 3 days demonstrating extensive absorption. Any influence of release rates or food on absorption rates could not be detected. When administered after fasting either formulation was bioequivalent. Coadministration of a meal enhanced ISDN plasma levels in some subjects although no statistically significant difference in extent of bioavailability was observed. Availability of the mononitrates was unaffected by food.

UI MeSH Term Description Entries
D007548 Isosorbide Dinitrate A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action. Cardonit 40,Dilatrate,Iso-Bid,Isodinit,Isoket,Isoket Retard-120,Isomak R,Isordil,Isotrate,Nitrosorbide,Sorbitrate,Sorbonit,Dinitrate, Isosorbide,Iso Bid,IsoBid,Isoket Retard 120,Isoket Retard120
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D011786 Quality Control A system for verifying and maintaining a desired level of quality in a product or process by careful planning, use of proper equipment, continued inspection, and corrective action as required. (Random House Unabridged Dictionary, 2d ed) Control, Quality,Controls, Quality,Quality Controls
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D005243 Feces Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

L F Chasseaud, and T Taylor, and R M Major, and I W Taylor, and V Luckow, and A Darragh, and R F Lambe
September 1988, Arzneimittel-Forschung,
L F Chasseaud, and T Taylor, and R M Major, and I W Taylor, and V Luckow, and A Darragh, and R F Lambe
June 1982, Journal of pharmaceutical sciences,
L F Chasseaud, and T Taylor, and R M Major, and I W Taylor, and V Luckow, and A Darragh, and R F Lambe
January 1990, Clinical therapeutics,
L F Chasseaud, and T Taylor, and R M Major, and I W Taylor, and V Luckow, and A Darragh, and R F Lambe
August 1983, International journal of clinical pharmacology, therapy, and toxicology,
L F Chasseaud, and T Taylor, and R M Major, and I W Taylor, and V Luckow, and A Darragh, and R F Lambe
January 1981, Arzneimittel-Forschung,
L F Chasseaud, and T Taylor, and R M Major, and I W Taylor, and V Luckow, and A Darragh, and R F Lambe
January 1991, Indian heart journal,
L F Chasseaud, and T Taylor, and R M Major, and I W Taylor, and V Luckow, and A Darragh, and R F Lambe
January 1980, Chest,
L F Chasseaud, and T Taylor, and R M Major, and I W Taylor, and V Luckow, and A Darragh, and R F Lambe
October 1997, Biological & pharmaceutical bulletin,
L F Chasseaud, and T Taylor, and R M Major, and I W Taylor, and V Luckow, and A Darragh, and R F Lambe
January 1981, Arzneimittel-Forschung,
L F Chasseaud, and T Taylor, and R M Major, and I W Taylor, and V Luckow, and A Darragh, and R F Lambe
January 1985, European journal of clinical pharmacology,
Copied contents to your clipboard!